QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has achieved CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel that sets a new benchmark in the diagnosis of central nervous system (CNS) infections.

Altesa BioSciences, a clinical stage pharmaceutical company dedicated to preventing and treating rhinovirus infections, one of the leading causes of Chronic Obstructive Pulmonary Disease (COPD) and asthma exacerbations, today announced a partnership with bioMérieux, a world leader in the field of in vitro diagnostics, to utilize the BIOFIRE® SPOTFIRE® respiratory solution as its core point-of-care diagnostics platform at U.S. sites for Altesa’s upcoming Phase 2B clinical trial.

Epigenetics firm VolitionRx and Werfen said Tuesday that they have signed a licensing and commercialization deal covering the use of Volition's antiphospholipid syndrome (APS) test with Werfen's analyzers.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic partnership with PathGroup, one of the nation’s leading partners to physicians, hospitals, and healthcare networks nationwide, to significantly expand the reach of Guardant’s FDA-approved Shield™ blood test. The partnership will bring Shield to more than 250 hospitals and health systems, over 15,000 PathGroup-affiliated physicians across 25 states, and allow more patients to benefit from Guardant’s industry-leading Shield blood test for early cancer detection through PathGroup’s large network of EMR hospital integrations and phlebotomists. More than five million patients each year receive testing through PathGroup.

Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2025.

Siemens Partners with Rejoin Medical to Build a Digital Future for Sports Medicine Medical Devices Siemens Industrial Software (Shanghai) Co., Ltd. and Rejoin Medical recently officially s..

Octave Bioscience, Inc., a commercial stage precision care company that is pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announces the close of its $35.6 million Series C equity financing and that it has entered into a $15.5 million non-dilutive term loan agreement with Silicon Valley Bank (SVB) a Division of First Citizens Bank.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE IVDR approval for two label expansions for its VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* assay. HER2 is a receptor protein expressed in a variety of cancers and serves as a predictive biomarker to help determine if a patient will respond to HER2-targeted therapy.

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 3, under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2025.

Siemens Healthineers and Evident said Wednesday that they are partnering on the delivery of a digital pathology workflow to the German nonprofit teaching hospital Klinikum der Stadt Ludwigshafen am Rhein.

Cyted Health, a leading gastrointestinal (GI) molecular diagnostics company, today announces a first close of $44 million in its Series B financing round to accelerate its ongoing US expansion.

Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the closing of a $59 million series B financing. The round was co-led by Novalis and Sozo Ventures, with participation from Perceptive Xontogeny Venture Funds, American Cancer Society BrightEdge, and iSelect Fund, as well as funds committed to women’s health and leadership including Portfolia, Avestria Ventures, and Mindshift Capital. The round also included significant participation from strategic investors including Hologic, Bruker Scientific, and Labcorp.

Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR) as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab). MMR IHC Panel pharmDx (Dako Omnis) is approved for exclusive use with the Agilent Dako Omnis automated staining solution.

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the completion of its acquisition of the Purification & Filtration business of Solventum (NYSE: SOLV) for approximately $4.0 billion in cash. With the transaction complete, the business, which is now Thermo Fisher’s Filtration and Separation business, is part of the Life Sciences Solutions segment.

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the completion of its acquisition of Sanofi’s state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey, marking an expansion of the companies’ strategic partnership to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. The Ridgefield facility is now part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment.

2.1 Blood Coagulation Analyzers Coagulation analyzers are mainly applied for laboratory tests of thrombosis and hemostasis, which can provide valuable indicators for the diagnosis and differential diagnosis of h..

Sansure Biotech 21% Revenue Growth, Overseas Business Up 60% in H1 2025 Sansure Biotech Inc. announced its 2025 half-year financial results, recording revenue of RMB 869 million, a 21.15% year-on-year in..

Original from: QIAGEN · U.S. market entry set to begin for QIAstat-Dx Rise – a version of QIAstat-Dx for syndromic testing that combines unparalleled throughput with the easiest workflow · QIAst..

SmartLabs and Sonrai Analytics (Sonrai) today announced a global strategic partnership designed to bring Sonrai's next-generation AI capabilities directly into SmartLabs' network of advanced research centers. Under this agreement, SmartLabs will begin offering Sonrai's AI advanced analytics platform, Sonrai Discovery, to its member companies. Both companies will also develop new laboratory informatics and bespoke AI applications that will integrate experimental and infrastructure data to predict scientific outcomes and accelerate discovery, exclusively to the SmartLabs' network.

Original from: genome web MGI Tech has reported that its revenues for the first half of 2025 dropped 8 percent year over year, mainly due to declining instrument sales. According to a filin..